Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States

References

• Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545–1551
   PubMed Web of Science ®Google Scholar
• Reddy N, Oluwole O, Greer JP, et al. Outcomes of autologous and allogeneic stem cell transplantation for non-Hodgkin’s lymphoma. Exp Hematol. 2014;42:39–45.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J. The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. Blood. 2016;127:2093–2100.
   PubMed Web of Science ®Google Scholar
• Epperia N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Cell Ther. 2017;10:277–284.
   PubMedGoogle Scholar
• High-Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin’s Lymphoma. American Cancer Society. [cited 2018 Jan]. Available from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/bone-marrow-stem-cell.html
   Google Scholar
• Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51:778–785.
   PubMed Web of Science ®Google Scholar
• Broder M, Quock T, Change E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10:366–374.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48:294–300.
   PubMed Web of Science ®Google Scholar
• Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14:197–207.
   PubMed Web of Science ®Google Scholar
• Svahn BM, Remberger M, et al. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2012;47:706–715.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mothukuri JM, Brunstein CG, et al. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009;15:564–573.
   PubMed Web of Science ®Google Scholar
• Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the national inpatient sample. Cancer. 2008;112:1096–1105.
   PubMed Web of Science ®Google Scholar
• Healthcare Cost and Utilization Project (HCUP). The National Inpatient Sample Overview. [cited 2018 Apr]. Available from: https://www.hcup-us.ahrq.gov/nisoverview.jsp
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). HCUP Nationwide Inpatient Sample (NIS). [cited 2018 Jan]. Available from: https://www.hcup-us.ahrq.gov/nisoverview.jsp#multi
   Google Scholar
• Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944–953.
   PubMed Web of Science ®Google Scholar
• Vicki Stagg. "CHARLSON: Stata module to calculate Charlson index of comorbidity," Statistical Software. 2006 [cited 2016 Aug]. Available from: https://ideas.repec.org/c/boc/bocode/s456719.html
   Google Scholar
• Cost-to-Charge Ratio Files. Healthcare Cost and Utilization Project (HCUP). September 2018. Agency for Healthcare Research and Quality, Rockville, MD. Available from: www.hcup-us.ahrq.gov/db/state/costtocharge.jsp
   Google Scholar
• Bureau of Labor Statistics. United States Department of Labor. [cited 2018 Jan]. Available from: https://www.bls.gov/data/
   Google Scholar
• Fisher ES, Bynum JP, Skinner JS. Slowing the growth of health care costs–lessons from regional variation. N Engl J Med. 2009;360:849–852.
   PubMed Web of Science ®Google Scholar
• Sloan FA, Picone GA, Taylor DH, et al. Hospital ownership and cost and quality of care: is there a dime's worth of difference? J Health Econ. 2001;20:1–21.
   PubMed Web of Science ®Google Scholar
• Tompkin CP, Altman SH, Eliat E. The precarious pricing system for hospital services. Health Aff (Millwood). 2006;25:45–56.
   PubMed Web of Science ®Google Scholar
• U.S. Transplant Data by Disease Report. Health Resources and Services Administration. U.S. Department of Health and Human Services. [cited 2018 Aug]. Available from: https://bloodcell.transplant.hrsa.gov/research/transplant_data/us_tx_data/data_by_disease/national.aspx
   Google Scholar
• Panch SR, Szymanski J, Savani BN, et al. Sources of hematopoietic stem and progenitor cells and methods to optimize yields for clinical cell therapy. Biol Blood Marrow Transplant. 2017;23:1241–1249.
   PubMed Web of Science ®Google Scholar
• Consumer Price Index in Medical Care. Bureau of Labor Statistics. United States Department of Labor. [cited 2018 Apr]. Available from: https://data.bls.gov/cgi-bin/surveymost?cu
   Google Scholar
• Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant. 2011;17:1146–1153.
   PubMed Web of Science ®Google Scholar
• Graff T, Singavi A, Schmidt W, et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015;50:947–953.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klar N, Weeks JC, et al. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71.
   PubMed Web of Science ®Google Scholar
• Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15:757–766.
   PubMed Web of Science ®Google Scholar
• Iezzoni L. Risk adjustment for measuring health care outcomes. 3rd ed. Chicago, IL: Health Administration Press; 2003.
   Google Scholar
• Cao Z, Villa KF, Lipkin CB, et al. Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation. J Med Econ. 2017;20:871–883.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–1269.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008;83:1131–1138.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar